REGNRegeneron Pharmaceuticals, Inc.
AI adoption · Q1 2026 earnings call
Health CareExploring
1
extracted from this call
2 / 5
directional only
Not disclosed
no breakout in this call
Artificial intelligence, machine learning, and related technologies were not meaningfully discussed on this call. The sole reference with any potential AI adjacency was a collaboration with TriNetX to access de-identified electronic health record data from a global network of 300 million patients to connect genomic and proteomic cohorts to real-world clinical data, which management framed as accelerating drug discovery and addressing 'digital health issues.' No AI products, AI infrastructure investments, AI partnerships with technology companies, or AI-driven productivity initiatives were mentioned.
Beneficiary
See full leaderboard →10/ 100
24
stage: exploring · max spec: 2
0
no quantified disclosure
0
no adoption scopes
1 AI mention from this call.
Extracted verbatim from the REGN Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T2Prepared remarks· Other· Customer demand signal
“creating an opportunity to connect large-scale genomic and proteomic cohorts to real-world clinical data in ways that can accelerate drug discovery, translation, development as well as providing new ways of addressing digital health issues”
— George Yancopoulos, REGN earnings callTriNetX
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No discussion of AI or machine learning use in internal drug discovery, despite the Regeneron Genetics Center being highlighted as a key R&D asset.
- The TriNetX collaboration references 'digital health issues' without elaborating on whether AI/ML tools are involved in data analysis.
- No analyst questions were directed at AI strategy, AI-enabled drug discovery, or AI infrastructure.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.